ProShare Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $634K | Sell |
22,040
-1,998
| -8% | -$57.5K | ﹤0.01% | 985 |
|
|
2025
Q1 | $806K | Sell |
24,038
-5,051
| -17% | -$169K | ﹤0.01% | 875 |
|
|
2024
Q4 | $1.49M | Buy |
29,089
+9,655
| +50% | +$494K | ﹤0.01% | 767 |
|
|
2024
Q3 | $993K | Buy |
19,434
+5,730
| +42% | +$293K | ﹤0.01% | 815 |
|
|
2024
Q2 | $614K | Sell |
13,704
-3,027
| -18% | -$136K | ﹤0.01% | 875 |
|
|
2024
Q1 | $783K | Buy |
16,731
+1,655
| +11% | +$77.5K | ﹤0.01% | 864 |
|
|
2023
Q4 | $536K | Buy |
15,076
+3,105
| +26% | +$110K | ﹤0.01% | 996 |
|
|
2023
Q3 | $356K | Buy |
11,971
+1,540
| +15% | +$45.8K | ﹤0.01% | 1114 |
|
|
2023
Q2 | $188K | Buy |
+10,431
| New | +$188K | ﹤0.01% | 1555 |
|
|
2023
Q1 | – | Sell |
-11,222
| Closed | -$205K | – | 1817 |
|
|
2022
Q4 | $205K | Buy |
11,222
+913
| +9% | +$16.7K | ﹤0.01% | 1482 |
|
|
2022
Q3 | $204K | Buy |
10,309
+230
| +2% | +$4.55K | ﹤0.01% | 1400 |
|
|
2022
Q2 | $188K | Sell |
10,079
-3,480
| -26% | -$64.9K | ﹤0.01% | 1491 |
|
|
2022
Q1 | $298K | Sell |
13,559
-3,196
| -19% | -$70.2K | ﹤0.01% | 1634 |
|
|
2021
Q4 | $476K | Buy |
16,755
+3,721
| +29% | +$106K | ﹤0.01% | 1484 |
|
|
2021
Q3 | $274K | Sell |
13,034
-3,183
| -20% | -$66.9K | ﹤0.01% | 1611 |
|
|
2021
Q2 | $306K | Buy |
16,217
+4,431
| +38% | +$83.6K | ﹤0.01% | 1883 |
|
|
2021
Q1 | $180K | Buy |
11,786
+711
| +6% | +$10.9K | ﹤0.01% | 2066 |
|
|
2020
Q4 | $156K | Buy |
+11,075
| New | +$156K | ﹤0.01% | 1909 |
|
|
2019
Q2 | – | Sell |
-9,098
| Closed | -$207K | – | 1632 |
|
|
2019
Q1 | $207K | Buy |
9,098
+217
| +2% | +$4.94K | ﹤0.01% | 1457 |
|
|
2018
Q4 | $266K | Buy |
+8,881
| New | +$266K | ﹤0.01% | 1214 |
|